325 related articles for article (PubMed ID: 34096584)
21. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
Simons LA; Ortiz M; Freedman SB; Waterhouse BJ; Colquhoun D; Thomas G
Curr Med Res Opin; 2016 Nov; 32(11):1857-1861. PubMed ID: 27463735
[TBL] [Abstract][Full Text] [Related]
22. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
Kim H; Lee YS; Kim TH; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Shim J; Uhm JS; Park HW; Choi EK; Kim JB; Kim C; Kim J; Joung B
Korean J Intern Med; 2020 Jan; 35(1):99-108. PubMed ID: 31014064
[TBL] [Abstract][Full Text] [Related]
23. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
[TBL] [Abstract][Full Text] [Related]
24. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
25. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation.
Kim D; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Sung JH; Pak HN; Lee MH; Lip GYH; Joung B
Europace; 2021 Feb; 23(2):184-195. PubMed ID: 33063123
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
[TBL] [Abstract][Full Text] [Related]
27. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
[TBL] [Abstract][Full Text] [Related]
28. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
30. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk.
Komen JJ; Heerdink ER; Klungel OH; Mantel-Teeuwisse AK; Forslund T; Wettermark B; Hjemdahl P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f72-f80. PubMed ID: 32324233
[TBL] [Abstract][Full Text] [Related]
31. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
32. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
34. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
35. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study.
Huang HK; Liu PP; Lin SM; Hsu JY; Peng CC; Munir KM; Wu TY; Yeh JI; Loh CH; Tu YK
Diabetes Obes Metab; 2021 Feb; 23(2):499-507. PubMed ID: 33140538
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
38. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Loh CH
Eur Heart J; 2020 Mar; 41(10):1100-1108. PubMed ID: 32006423
[TBL] [Abstract][Full Text] [Related]
39. Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
Hwang HJ; Sohn IS; Jin ES; Bae YJ
PLoS One; 2023; 18(3):e0283478. PubMed ID: 36996134
[TBL] [Abstract][Full Text] [Related]
40. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
